RESUMO
Objective To provide evidences which are for clinicians to formulate effective prevention and treatment measures by analyzing the perinatal pregnant women vaginal group B streptococcus (GBS)infection and adverse pregnancy outcomes. Methods From January 2013 to February 2015,the vaginal secretions were sampled from 795 cases of perinatal pregnant women for culture identification of GBS,the final results were statistical analyzed.Results In the 795 pregnant women ca-ses,there were 256 GBS carriers cases,the carrier rate was 32.2%.There was statistically significance (χ2 = 19.095,P <0.01)between less than 30 years old group (28.9%)and greater than or equal to 30 years old group (42.3%).The differ-ent incidence rate of clinical symptoms between GBS negative cases and GBS positive cases (18.8% vs 8.0%)was also had statistically significance (χ2 =39.514,P <0.01).The antimicrobial resistant rates of ten kinds of antibacterial drugs (vanco-mycin,linezolid,penicillin,ampicillin,ceftriaxone,nitrofurantoin,levofloxacin,clindamycin,erythromycin and tetracycline) was 0,0,0.6%,3.1%,6.6%,9.6%,21.9%,23.8%,29.9% and 58.1% respectively.The positive rate of D-bacteriostatic ring experiment was 23.9%.Conclusion The carrier rate of perinatal pregnant women GBS was higher in this region,and the elderly were easier to be infected.Perinatal pregnant women infected with GBS to vancomycin and rina thiazole amine and penicillin and ampicillin and ceftriaxone and with nitrofurantoin because of the sensitive rate is high.
RESUMO
<p><b>OBJECTIVE</b>To observe the effective mechanism and side effects of thalidomide to multiple myeloma (MM).</p><p><b>METHODS</b>Ten cases of MM were studied, of which 3 were previously untreated and 7 refractory or relapsed. Bone marrow microvascular density (MVD) was detected by factor-VIII related antigen and CD(34) immunohistological staining and serum concentration of vascular endothelial growth factor (VEGF) before and after treatment was determined by ELISA. The initial dosage of thalidomide was 100 approximately 200 mg/d with a weekly escalation of 50 mg/d to 450 approximately 650 mg/d. The therapeutic effectiveness is classified into partial remission, improvement and uneffective according to the decrease of serum M protein and bone marrow myeloma cells. Anemia, renal function and blood electrolytes were also observed.</p><p><b>RESULTS</b>Before treatment, MVD was 73.32 +/- 28.80 and 32.30 +/- 12.50 in MM and control group, respectively, (P < 0.01). MVD in MM group decreased to 56.12 +/- 19.34 after treatment, and was of significant difference (P < 0.05) as compared to the pretreatment value. However, there was still a significant difference as compared to control (56.12 +/- 19.34 vs 32.30 +/- 12.50, P < 0.01). The concentration of VEGF significantly decreased after treatment [from (178.23 +/- 26.56) ng/L to (78.48 +/- 19.98) ng/L, P < 0.01)]. The total effective rate was 70%. There were no serious side effects.</p><p><b>CONCLUSION</b>MVD and VEGF concentration were decreased obviously by thalidomide treatment. The dosage of 450 approximately 650 mg/d might be effective in refractory or initial MM.</p>